News

Catabasis Pharmaceuticals Begins MoveDMD Trial For The Treatment of Duchenne Muscular Dystrophy

Massachusetts based Catabasis Pharmaceuticals,  a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on their proprietary pathway pharmacology technology platform, recently announced that they have begun treating patients in their MoveDMD trial, a Phase 1/2 trial of CAT- 1004 for the treatment of Duchenne…

Provia Reports Record Enrollment for Store-a-Toothâ„¢ Dental Stem Cell Technology

Grace Century’s bio banking project, Provia Laboratories, LLC, a healthcare services company specializing in high-quality bio-banking (the collection, transport, processing and cryogenic storage of biological specimens), recently reported 47% quarterly growth in enrollments for their Store-a-Toothâ„¢ cryogenic storage service of dental stem cells. Store-A-Tooth is committed to offering…

Akashi Therapeutics Announces Positive Results of HT-100 for Duchenne Muscular Dystrophy

Akashi Therapeutics Inc. a biopharmaceutical company focused on developing treatments for patients with Duchenne muscular dystrophy (DMD) recently announced encouraging interim results of its ongoing Phase 1b/2a clinical trial of HT-100 (delayed-release halofuginone) an orally available small molecule to reduce inflammation and fibrosis while promoting the regeneration of…